EXPC SEC filings, in plain English
Everything Experience Investment Corp. has filed with the SEC that we hold — 40 filings, newest first, 3 with a plain-English summary of what changed and why it matters. Every row links to the primary document on EDGAR, so you can check the source rather than trust us.
The feed
live EDGAR captureNew filings appear here within minutes of hitting EDGAR; summaries follow once the pipeline has read them.
What changed: Q2 2026 10-Q of Strata Critical Medical, Inc. (Nasdaq: SRTA). Revenue rose to $72,506 thousand for the quarter from $45,108 thousand and to $139,890 thousand for the six months from $81,056 thousand; gross profit was $15,215 thousand against $9,007 thousand. Operating expenses rose to $20,623 thousand from $13,648 thousand, including amortization of intangible assets of $6,627 thousand against $356 thousand, giving an operating loss from continuing operations of $(5,408) thousand. Why it matters: Revenue rose 61% and the balance sheet shows why: goodwill and intangibles grew $31.2 million over the half-year while cash and short-term investments fell $38.5 million, so acquisitions were paid for out of liquidity. Intangible amortization alone is now larger than the operating loss.
What changed: Exhibit 99.1 to an 8-K of Strata Critical Medical, Inc. (Nasdaq: SRTA): the August 4, 2026 press release reporting Q2 2026 results on a continuing-operations basis, with the divested Passenger business reclassified as discontinued operations in all periods. Total revenue rose 60.7% to $72,506 thousand, comprising Logistics of $48,240 thousand (up 6.9%) and Clinical of $24,266 thousand — Transplant Clinical $12,521 thousand and Other Clinical $11,745 thousand — for which no prior-year comparison is presented. Why it matters: Nearly all the revenue growth is the new Clinical segment, which did not exist in the prior-year period, so the 60.7% headline is not organic. Adjusted EBITDA more than tripled while the GAAP net loss also tripled, the gap being intangible amortization from the acquisitions.
What changed: Strata Critical Medical, Inc., formerly known as Blade Air Mobility and the successor to Experience Investment Corp., called its annual meeting for Thursday, May 28, 2026 at 9:00 a.m. Eastern Time as a virtual meeting, to elect two Class II directors to terms expiring at the 2029 annual meeting. After the meeting the Board is expected to consist of seven directors. Beneficial ownership is based on 86,446,690 shares outstanding as of March 31, 2026 and excludes 16,775,892 shares issuable on exercise of vested Strata options. Why it matters: The swing to $41.3 million of net income from a $27.3 million loss, alongside a rebrand from Blade Air Mobility to Strata Critical Medical, marks a completed pivot of the business the Experience Investment SPAC took public. The offsetting figure is 16,775,892 shares issuable on vested options excluded from the 86.4 million count - roughly 19% of additional dilution sitting outside the headline share number, plus earnout PSUs tested at February 28, 2027.
In plain English
Redemption deadlinethe last day to hand shares back for cash
Set by the filing that calls the meeting. Tender after it and the company is under no obligation to pay you the trust value.
Cash in trust / trust per sharethe cash the company is holding for each public share
Filed quarterly in the 10-Q's XBRL. It earns interest between filings, so the figure on a given day is slightly higher than the last filed one — where we show that we label it an estimate.
Accession numberthe SEC's unique id for one filing
Every figure on this page carries the accession of the filing that states it, so you can open the primary document rather than trust us.